JPS63295566A - キノキサリノン誘導体 - Google Patents

キノキサリノン誘導体

Info

Publication number
JPS63295566A
JPS63295566A JP62267597A JP26759787A JPS63295566A JP S63295566 A JPS63295566 A JP S63295566A JP 62267597 A JP62267597 A JP 62267597A JP 26759787 A JP26759787 A JP 26759787A JP S63295566 A JPS63295566 A JP S63295566A
Authority
JP
Japan
Prior art keywords
mol
dihydro
quinoxalinone
ethyl acetate
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP62267597A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0536436B2 (2
Inventor
レインハード・サージエス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of JPS63295566A publication Critical patent/JPS63295566A/ja
Publication of JPH0536436B2 publication Critical patent/JPH0536436B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
JP62267597A 1986-10-30 1987-10-22 キノキサリノン誘導体 Granted JPS63295566A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WO86/02335 1986-10-30
PCT/US1986/002335 WO1992005160A1 (en) 1986-10-30 1986-10-30 4-arylsulfonyl-3,4-dihydro-2(1h)-quinoxalinone-1-alkanoic acids, esters, and salts

Publications (2)

Publication Number Publication Date
JPS63295566A true JPS63295566A (ja) 1988-12-01
JPH0536436B2 JPH0536436B2 (2) 1993-05-31

Family

ID=22195697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62267597A Granted JPS63295566A (ja) 1986-10-30 1987-10-22 キノキサリノン誘導体

Country Status (11)

Country Link
US (1) US4940708A (2)
EP (1) EP0266102B1 (2)
JP (1) JPS63295566A (2)
AT (1) ATE86985T1 (2)
DE (1) DE3784835T2 (2)
DK (1) DK561487A (2)
ES (1) ES2046206T3 (2)
GR (1) GR3007402T3 (2)
IE (1) IE68851B1 (2)
PT (1) PT85998B (2)
WO (1) WO1992005160A1 (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940708A (en) * 1986-10-30 1990-07-10 Pfizer Inc. 4-arylsulfonyl-3,4-dihydro-2(1H)-quinoxalinone-1-alkanoic acids, esters, and salts
US6369057B1 (en) 1991-04-15 2002-04-09 Aventis Pharma Deutschland Gmbh Quinoxalines, processes for their preparation and their use
PT509398E (pt) * 1991-04-15 2002-02-28 Aventis Pharma Gmbh Quinoxalinas processo para a sua preparacao e sua utilizacao
US7351709B2 (en) 2004-06-09 2008-04-01 Wyeth Estrogen receptor ligands
EP1940805A4 (en) * 2005-08-26 2009-11-11 Methylgene Inc BENZODIAZEPIN AND BENZOPIPERAZINANALOGA AS INHIBITORS OF HISTONDEACETYLASE
BRPI0911588B1 (pt) 2008-04-30 2018-07-17 Xyleco Inc método de preparo de um material de ração
US8236535B2 (en) 2008-04-30 2012-08-07 Xyleco, Inc. Processing biomass
US8212087B2 (en) 2008-04-30 2012-07-03 Xyleco, Inc. Processing biomass
US7867358B2 (en) 2008-04-30 2011-01-11 Xyleco, Inc. Paper products and methods and systems for manufacturing such products
KR101793398B1 (ko) 2008-10-28 2017-11-02 질레코 인코포레이티드 탄화수소-함유 재료의 처리방법
WO2022109292A1 (en) * 2020-11-20 2022-05-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for inhibiting cb1 activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821383A (en) * 1972-07-10 1974-06-28 Ayerst Mckenna & Harrison Compositions for and a method of treating diabetic complications
US4209527A (en) * 1979-05-16 1980-06-24 Pfizer Inc. Benzimidazolone derivatives
US4940708A (en) * 1986-10-30 1990-07-10 Pfizer Inc. 4-arylsulfonyl-3,4-dihydro-2(1H)-quinoxalinone-1-alkanoic acids, esters, and salts

Also Published As

Publication number Publication date
PT85998A (en) 1987-11-01
IE872877L (en) 1988-04-28
EP0266102A2 (en) 1988-05-04
DE3784835D1 (de) 1993-04-22
EP0266102A3 (en) 1989-11-23
GR3007402T3 (2) 1993-07-30
DK561487D0 (da) 1987-10-27
JPH0536436B2 (2) 1993-05-31
DK561487A (da) 1988-08-08
IE68851B1 (en) 1996-07-24
DE3784835T2 (de) 1993-06-24
ES2046206T3 (es) 1994-02-01
WO1992005160A1 (en) 1992-04-02
PT85998B (pt) 1990-08-31
EP0266102B1 (en) 1993-03-17
US4940708A (en) 1990-07-10
ATE86985T1 (de) 1993-04-15

Similar Documents

Publication Publication Date Title
CA1265517A (fr) DERIVES DE L'ACIDE .alpha.-[OXO-2 HEXAHYDRO-2,4,5,6,7, 7A THIENO (3,2-C) PYRIDYL-5] PHENYL ACETIQUE, LEUR PROCEDE DE PREPARATION ET LEUR APPLICATION THERAPEUTIQUE
EP0202164B1 (fr) Dérivés de (benzoyl-4 pipéridino)-2 phenyl-1 alcanols, leur préparation et leur application en thérapeutique
US20040068109A1 (en) Diazepan derivatives or salts thereof
HU179746B (en) Process for producing new spiro-oxasolidines
FR2477542A1 (fr) Derives de carbostyrile, leurs procedes de preparation et leur application en therapeutique
FI93013C (fi) Menetelmä terapeuttisesti käyttökelpoisten pyridopyridatsinonijohdannaisten valmistamiseksi
JP2835731B2 (ja) ピペリジニル化合物類
JPH01265100A (ja) ２―置換アデノシン誘導体
JPS6210508B2 (2)
JPS63295566A (ja) キノキサリノン誘導体
EP0257864B1 (en) Antiarrhythmic agents
CA1327364C (fr) ¬(diarylmethoxy)alcoyl|-1 pyrrolidines et piperidines, procede de preparation et medicaments les contenant
US4134991A (en) Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid
EP0148167B1 (fr) Nouveaux dérivés de la quinoléine, leur procédé de préparation et les compositions pharmaceutiques les renfermant
JPH0460597B2 (2)
EP0019440B1 (en) Benzimidazolone derivatives, process for their preparation and pharmaceutical compositions containing them
JPH07502007A (ja) 治療用のベンズアザピン化合物
EP0718307A2 (fr) Dérivés de 1-oxo-2-(phénylsulfonyl-amino)pentylpipéridine, leur préparation et leur application en thérapeutique
JPH09301963A (ja) Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
JPH09278737A (ja) フェノール誘導体及びその製法
JPH08143566A (ja) キナゾリン誘導体及びそれを含有する医薬組成物
HU198917B (en) Process for producing 2,1-benzothiazepine-2,2-dioxide-5-carboxylic acid derivatives and pharmaceutical compositions containing them
JPH09295977A (ja) ピリドピリミジン誘導体及びそれを含有する医薬組成物
KR790001695B1 (ko) 벤즈사이클로아미드 유도체의 제조법
JPS60246376A (ja) Ｎ置換３，４−ジヒドロピリミジン誘導体、その製造方法および循環系疾患治療剤